Otsuka’s Voyxact preserves kidney function at 12 months

Otsuka’s Voyxact was granted accelerated approval from the FDA in November 2025 based on nine-month data. Otsuka’s Voyxact was granted accelerated approval from the FDA in November 2025 based on nine-month data. Otsuka Pharmaceutical presented the 12 month data at ERA 2026. Credit: Piotr Swat/SOPA Images/LightRocket via Getty Images) Otsuka Pharmaceutical’s Voyxact (sibeprenlimab-szsi) has preserved kidney function for 12 months in patients with primary IgA nephropathy (IgAN) in a Phase III trial. In the VISIONARY study (NCT05248646), patients treated with Voyxact saw a 0.7 mL/min/1.73 m2 increase in estimated glomerular filtration rate (eGFR) compared to a decline of 4.8 mL/min/1.73…

Source: Clinical Trials Arena